BioSpace - AbCellera's ABCL-635 'Sets New Efficacy Bar' for Hot Flashes (Aug 11, 2026)

Tier 2: Professional organization or credentialed expert guidance
Publisher: BioSpace / Femtech Insider / Barron's · Published: August 11, 2026 · Accessed: August 14, 2026

Visit the source ↗

Claims this source supports

• BioSpace (Aug 11, 2026) reported that AbCellera's ABCL-635, an investigational NK3-receptor antibody for hot flashes, reduced moderate-to-severe vasomotor symptoms 83% versus baseline in Phase 2 and was described as setting a new efficacy bar for the class.
• Coverage (Aug 10-11, 2026) noted the company's shares rose roughly 34% following the Phase 2 announcement.
• AbCellera subsequently announced (Aug 11-12, 2026) an oversubscribed $200 million public offering; the company confirmed the raise on its own newsroom.